{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:06:16Z","timestamp":1791515176947,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,10,19]],"date-time":"2011-10-19T00:00:00Z","timestamp":1318982400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00592-011-0340-7","type":"journal-article","created":{"date-parts":[[2011,10,18]],"date-time":"2011-10-18T10:47:58Z","timestamp":1318934878000},"page":"569-577","source":"Crossref","is-referenced-by-count":85,"title":["The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database"],"prefix":"10.1007","volume":"50","author":[{"given":"E.","family":"Raschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Marchesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,19]]},"reference":[{"key":"340_CR1","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1046\/j.1365-2036.2003.01485.x","volume":"17","author":"RJ Lancashire","year":"2003","unstructured":"Lancashire RJ, Cheng K, Langman MJ (2003) Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. Aliment Pharmacol Ther 17:887\u2013893","journal-title":"Aliment Pharmacol Ther"},{"key":"340_CR2","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.cgh.2006.11.023","volume":"5","author":"N Badalov","year":"2007","unstructured":"Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S (2007) Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 5:648\u2013661","journal-title":"Clin Gastroenterol Hepatol"},{"key":"340_CR3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2165\/00002018-200831100-00002","volume":"31","author":"AR Balani","year":"2008","unstructured":"Balani AR, Grendell JH (2008) Drug-induced pancreatitis: incidence, management and prevention. Drug Saf 31:823\u2013837","journal-title":"Drug Saf"},{"key":"340_CR4","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/dc08-1755","volume":"32","author":"RA Noel","year":"2009","unstructured":"Noel RA, Braun DK, Patterson RE, Bloomgren GL (2009) Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 32:834\u2013838","journal-title":"Diabetes Care"},{"key":"340_CR5","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.2337\/dc10-0842","volume":"33","author":"A Gonzalez-Perez","year":"2010","unstructured":"Gonzalez-Perez A, Schlienger RG, Rodriguez LA (2010) Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 33:2580\u20132585","journal-title":"Diabetes Care"},{"key":"340_CR6","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1463-1326.2010.01231.x","volume":"12","author":"CJ Girman","year":"2010","unstructured":"Girman CJ, Kou TD, Cai B, Alexander CM, O\u2019Neill EA, Williams-Herman DE, Katz L (2010) Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 12:766\u2013771","journal-title":"Diabetes Obes Metab"},{"key":"340_CR7","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2337\/dc10-0482","volume":"33","author":"R Garg","year":"2010","unstructured":"Garg R, Chen W, Pendergrass M (2010) Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 33:2349\u20132354","journal-title":"Diabetes Care"},{"key":"340_CR8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/diacare.29.02.06.dc05-2043","volume":"29","author":"PS Denker","year":"2006","unstructured":"Denker PS, Dimarco PE (2006) Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 29:471","journal-title":"Diabetes Care"},{"key":"340_CR9","first-page":"987","volume":"56","author":"NR Tripathy","year":"2008","unstructured":"Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A (2008) Exenatide and acute pancreatitis. J Assoc Physicians India 56:987\u2013988","journal-title":"J Assoc Physicians India"},{"key":"340_CR10","first-page":"1970","volume":"358","author":"SR Ahmad","year":"2008","unstructured":"Ahmad SR, Swann J (2008) Exenatide and rare adverse events. N Engl J Med 358:1970\u20131971","journal-title":"N Engl J Med"},{"key":"340_CR11","unstructured":"US Food and Drug Administration (2007) Information for healthcare professionals: exenatide (marketed as Byetta)\u201410\/2007. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124712.htm . Accessed 6 June 2011"},{"key":"340_CR12","unstructured":"US Food and Drug Administration (2008) Information for healthcare professionals: exenatide (marketed as Byetta)\u20148\/2008 Update. http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm079781.htm . Accessed 6 June 2011"},{"key":"340_CR13","unstructured":"US Food and Drug Administration (2009) Information for healthcare professionals\u2014acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHealthcareProfessionals\/ucm183764.htm . Accessed 6 June 2011"},{"key":"340_CR14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1185\/03007990902820519","volume":"25","author":"DD Dore","year":"2009","unstructured":"Dore DD, Seeger JD, Arnold CK (2009) Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25:1019\u20131027","journal-title":"Curr Med Res Opin"},{"key":"340_CR15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2010.02382.x","volume":"64","author":"SS Engel","year":"2010","unstructured":"Engel SS, Williams-Herman DE, Golm GT, Clay RJ, Machotka SV, Kaufman KD, Goldstein BJ (2010) Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 64:984\u2013990","journal-title":"Int J Clin Pract"},{"key":"340_CR16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1463-1326.2011.01376.x","volume":"13","author":"DD Dore","year":"2011","unstructured":"Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, Braun DK, Noel RA, Seeger JD (2011) A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 13:559\u2013566","journal-title":"Diabetes Obes Metab"},{"key":"340_CR17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150\u2013156","journal-title":"Gastroenterology"},{"key":"340_CR18","doi-asserted-by":"crossref","first-page":"d2335","DOI":"10.1136\/bmj.d2335","volume":"342","author":"N Hawkes","year":"2011","unstructured":"Hawkes N (2011) Journal withdraws article after complaints from drug manufacturers. BMJ 342:d2335","journal-title":"BMJ"},{"key":"340_CR19","unstructured":"BMJ News (2011) Replies to \u201cJournal withdraws article after complaints from drug manufacturers\u201d. http:\/\/www.bmj.com\/content\/342\/bmj.d2335.full\/reply#bmj_el_256671 . Accessed 6 June 2011"},{"key":"340_CR20","unstructured":"European Association for the Study of Diabetes (2011) EASD commentary on the publication by Elashoff et al., published online in Gastroenterology, February 2011: Increased incidence of pancreatitis and cancer among patients given glucagon like peptide-1-based therapy. http:\/\/www.easd.org\/easdwebfiles\/statements\/Elashoff_Commentary.pdf . Accessed 6 June 2011"},{"key":"340_CR21","unstructured":"US Food and Drug Administration (2011) The adverse event reporting system (AERS): latest quarterly data files. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/ucm082193 . Accessed 6 June 2011"},{"key":"340_CR22","unstructured":"US Food and Drug Administration (2011) Drugs@FDA data files. http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ucm079750.htm . Accessed 6 June 2011"},{"key":"340_CR23","unstructured":"EUROMEDSTAT (2007) A project funded by the European Union Commission. http:\/\/www.euromedstat.cnr.it\/ . Accessed 6 June 2011"},{"key":"340_CR24","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2010) ATC\/DDD Index 2011. http:\/\/www.whocc.no\/atc_ddd_index\/ . Accessed 6 June 2011"},{"key":"340_CR25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/11531850-000000000-00000","volume":"33","author":"E Poluzzi","year":"2010","unstructured":"Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F (2010) Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA adverse event reporting system. Drug Saf 33:303\u2013314","journal-title":"Drug Saf"},{"key":"340_CR26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18:427\u2013436","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"340_CR27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Puijenbroek van","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3\u201310","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"340_CR28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1046\/j.1365-2125.2002.01569.x","volume":"53","author":"ML Bruin De","year":"2002","unstructured":"De Bruin ML, van Puijenbroek EP, Egberts AC, Hoes AW, Leufkens HG (2002) Non-sedating antihistamine drugs and cardiac arrhythmias\u2014biased risk estimates from spontaneous reporting systems? Br J Clin Pharmacol 53:370\u2013374","journal-title":"Br J Clin Pharmacol"},{"key":"340_CR29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 30:891\u2013898","journal-title":"Drug Saf"},{"key":"340_CR30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/sim.4780100409","volume":"10","author":"H Petri","year":"1991","unstructured":"Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577\u2013581","journal-title":"Stat Med"},{"key":"340_CR31","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00002018-200730060-00009","volume":"30","author":"M Hauben","year":"2007","unstructured":"Hauben M, Reich L, DeMicco J, Kim K (2007) \u2018Extreme duplication\u2019 in the US FDA adverse events reporting system database. Drug Saf 30:551\u2013554","journal-title":"Drug Saf"},{"key":"340_CR32","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2337\/dc10-2412","volume":"34","author":"C Piccinni","year":"2011","unstructured":"Piccinni C, Motola D, Marchesini G, Poluzzi E (2011) Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 34:1369\u20131371","journal-title":"Diabetes Care"},{"key":"340_CR33","doi-asserted-by":"crossref","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a Pharmaco Vigilance database. Br J Clin Pharmacol. doi: 10.1111\/j.1365-2125.2011.04037.x","DOI":"10.1111\/j.1365-2125.2011.04037.x"},{"key":"340_CR34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF03256706","volume":"22","author":"M Hauben","year":"2008","unstructured":"Hauben M, Hochberg A (2008) The importance of reporting negative findings in data mining. The example of exenatide and pancreatitis. Pharm Med 22:215\u2013219","journal-title":"Pharm Med"},{"key":"340_CR35","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","volume":"24","author":"NR Hartnell","year":"2004","unstructured":"Hartnell NR, Wilson JP (2004) Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 24:743\u2013749","journal-title":"Pharmacotherapy"},{"key":"340_CR36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2165\/11584390-000000000-00000","volume":"33","author":"HW Wang","year":"2010","unstructured":"Wang HW, Hochberg AM, Pearson RK, Hauben M (2010) An experimental investigation of masking in the US FDA adverse event reporting system database. Drug Saf 33:1117\u20131133","journal-title":"Drug Saf"},{"key":"340_CR37","unstructured":"Amylin Pharmaceuticals Inc (2006) New or modified indication for exenatide. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2006\/021773s002,s006ltr.pdf . Accessed 6 June 2011"},{"key":"340_CR38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2125.1994.tb04373.x","volume":"38","author":"B Begaud","year":"1994","unstructured":"Begaud B, Moride Y, Tubert-Bitter P, Chaslerie A, Haramburu F (1994) False-positives in spontaneous reporting: should we worry about them? Br J Clin Pharmacol 38:401\u2013404","journal-title":"Br J Clin Pharmacol"},{"key":"340_CR39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/dc10-1771","volume":"34","author":"MJ Willemen","year":"2011","unstructured":"Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG (2011) Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care 34:369\u2013374","journal-title":"Diabetes Care"},{"key":"340_CR40","unstructured":"Mini-Sentinel (2011) Health outcomes details evidence review\u2014pancreatitis. http:\/\/www.minisentinel.org\/foundational_activities\/related_projects\/details.aspx?ID=125 . Accessed 10 June 2011"},{"key":"340_CR41","unstructured":"AIFA\u2014Italian Medicines Agency (2011) Italian antidiabetic registry. http:\/\/antidiabetici.agenziafarmaco.it\/ . Accessed 10 June 2011"},{"key":"340_CR42","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1345\/aph.1P714","volume":"45","author":"PH Lee","year":"2011","unstructured":"Lee PH, Stockton MD, Franks AS (2011) Acute pancreatitis associated with liraglutide. Ann Pharmacother 45:e22","journal-title":"Ann Pharmacother"},{"key":"340_CR43","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.4158\/EP10383.CR","volume":"17","author":"CM Girgis","year":"2011","unstructured":"Girgis CM, Champion BL (2011) Vildagliptin-induced acute pancreatitis. Endocr Pract 17:e48\u2013e50","journal-title":"Endocr Pract"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-011-0340-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-011-0340-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-011-0340-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:57:32Z","timestamp":1559123852000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-011-0340-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,19]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["340"],"URL":"https:\/\/doi.org\/10.1007\/s00592-011-0340-7","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,19]]}}}